UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Check One): [X] Form 10-K [_] Form 20-F [_] Form 11-K [_] Form 10-Q
[_] Form N-SAR
For Period Ended: December 31, 2000
[_] Transition Report on Form 10-K
[_] Transition Report on Form 20-F
[_] Transition Report on Form 11-K
[_] Transition Report on Form 10-Q
[_] Transition Report on Form N-SAR
For the Transition Period Ended: ___________________
- --------------------------------------------------------------------------------
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commissions has
verified any information contained herein.
- --------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
- --------------------------------------------------------------------------------
Full Name of Registrant:
Nova Pharmaceutical, Inc.
- --------------------------------------------------------------------------------
Former Name if Applicable:
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
31712 Casino Drive, Suite 7B
- --------------------------------------------------------------------------------
City, State and Zip Code
Lake Elsinore, California 92530
- --------------------------------------------------------------------------------
PART II - Rules 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box, if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be
filed on or before the fifteenth calendar day following the prescribed
due date; or the subject quarterly report of transition report on Form
10-Q, or portion thereof will be filed on or before the fifth calendar
day following the prescribed due date; and
[_] (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
1
PART III - NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed time period. (Attach Extra Sheets if Needed).
There will be a delay in filing the Company's Annual Report on Form 10-KSB for
the year ended December 31, 2000 due to the Company's inability to file on a
timely basis. The Company expects to file its Annual Report by April 17, 2001
(fifteen days following the due date).
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification.
Robert Eggering (909) 245-4657
---------------------------- ----------- ------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities and Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed? If the
answer is no, identify report(s).
[X] Yes [_] No
---------------------------------------------------------------------------
---------------------------------------------------------------------------
---------------------------------------------------------------------------
Nova Pharmaceutical, Inc. has caused this notification to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Lake
Elsinore, California on April 3, 2001.
Nova Pharmaceutical, Inc.,
a Nevada corporation
By: /s/ Robert Eggering
--------------------------
Its: Chief Financial Officer
-------------------------
INSTRUCTION: The form may be signed by an executive office of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
- --------------------------------------------------------------------------------
ATTENTION:
Intentional misstatements or omissions of fact constitute
Federal Criminal Violations (See 18 U.S.C. 1001).
- --------------------------------------------------------------------------------
2